These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 578469)

  • 1. Pharmacological studies of o-chloro-alpha-[(tert.-butylamino)methyl]benzylalcohol hydrochloride (C-78), a new bronchodilator. III. Actions on the nervous systems and miscellaneous organs.
    Uesaka I; Kubo S; Matsubara I; Kasé Y
    Arzneimittelforschung; 1977 Jul; 27(7):1439-45. PubMed ID: 578469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. General pharmacological properties of the new vasodilator flosequinan.
    Ikezono K; Fujita S; Umezato M; Hosoki E; Toba Y; Kusunoki A; Shintani S
    Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. General pharmacology of the new antimuscarinic compound vamicamide.
    Yamamoto T; Honbo T; Tokoro K; Kojimoto Y; Kodama R; Ohtsuka M; Shimomura K
    Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological studies of mabuterol, a new selective beta 2-stimulant. III: Effects on the central nervous system, striated muscle and carbohydrate and lipid metabolism.
    Osada E; Sakaya S; Sanai K; Seri K
    Arzneimittelforschung; 1984; 34(11A):1652-8. PubMed ID: 6152158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. General pharmacological properties of UFT, a new type of anti-cancer agent consisting of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT) and uracil. I: Pharmacological analysis of the combined effect of FT and uracil.
    Yamamoto J; Toide K; Haruno A; Yoshimura Y; Unemi N
    Arzneimittelforschung; 1981; 31(8):1268-78. PubMed ID: 6794578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Profile of pharmacological actions of NAB 365 (clenbuterol), a novel broncholytic agent with selective activity on adrenergic beta2-receptors (author's transl)].
    Engelhardt G
    Arzneimittelforschung; 1976; 26(7a):1404-20. PubMed ID: 12768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. General pharmacological properties of the main metabolite of flosequinan.
    Fujita S; Ikezono K; Umezato M; Hosoki E; Toba Y; Ishikawa M; Kusunoki A; Shintani S
    Arzneimittelforschung; 1992 Oct; 42(10):1212-22. PubMed ID: 1335257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. General pharmacology of recombinant human basic fibroblast growth factor.
    Okumura M; Yajima M; Nishimura T; Ikeda H; Nishimori T
    Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [General pharmacological studies on tinofedrine (author's transl)].
    Jakovlev V; Thiemer K; Habersang S; Achterrath-Tuckermann U; von Schlichtegroll A; Sofia RD
    Arzneimittelforschung; 1978; 28(8):1335-43. PubMed ID: 582399
    [No Abstract]   [Full Text] [Related]  

  • 10. [General pharmacologic studies on the analgesic flupirtine].
    Jakovlev V; Achterrath-Tuckermann U; von Schlichtegroll A; Stroman F; Thiemer K
    Arzneimittelforschung; 1985; 35(1):44-55. PubMed ID: 4039152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. General pharmacological properties of the human corticotropin-releasing hormone corticorelin (human).
    Andoh K; Kimura T; Saeki I; Tabata R; Yamazaki S; Eguchi I; Hanazuka M; Horii D; Munt PL; Davis AS
    Arzneimittelforschung; 1994 Jun; 44(6):715-26. PubMed ID: 8053970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. General pharmacological properties of muroctasin.
    Kojima H; Hirohashi M; Kasai Y; Takasuna K; Fukumoto C; Akashi A
    Arzneimittelforschung; 1988 Jul; 38(7A):1002-9. PubMed ID: 3190791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 1st communication: effect on the central nervous system.
    Hirotsu I; Kihara T; Nakamura S; Hattori Y; Hatta M; Kitakaze Y; Takahama K; Hashimoto Y; Miyata T; Ishihara T
    Arzneimittelforschung; 1988 Oct; 38(10):1398-409. PubMed ID: 3196380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of suloctidil on the central and peripheral nervous systems].
    Nishi H; Watanabe T; Mori M
    Nihon Yakurigaku Zasshi; 1983 Sep; 82(3):191-212. PubMed ID: 6319248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of azelastine hydrochloride, a novel anti-allergic drug, on the central nervous system.
    Kaneko T; Kitahara A; Ozaki S; Takizawa K; Yamatsu K
    Arzneimittelforschung; 1981; 31(8):1206-12. PubMed ID: 6117290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. General pharmacology of recombinant human tumor necrosis factor. 2nd communication: effects on central nervous system functions.
    Kurumiya S; Miura Y; Nakatsuji K; Dodo M; Hori M; Ito T
    Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):225-31. PubMed ID: 2334465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. General pharmacology of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride. Effects on central nervous and sensory systems and other functions.
    Yamamoto S; Takemori E; Hasegawa Y; Nakao K; Inukai T; Nomura M; Morino K; Tsuchiyama M; Hasegawa K; Ikeda H
    Arzneimittelforschung; 1991 Jun; 41(6):602-7. PubMed ID: 1930347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. General pharmacological profile of the new anti-ulcer drug 3-[[[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl]methyl]-amino-N -methylbenzamide.
    Hirohashi M; Takasuna K; Kasai Y; Usui C; Tamura K; Kojima H
    Arzneimittelforschung; 1993 May; 43(5):569-77. PubMed ID: 8329002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of secoverine, a new spasmolytic agent with specific antimuscarinic properties. Part 2: General pharmacological properties.
    Zwagemakers JM; Claassen V
    Arzneimittelforschung; 1980; 30(9):1526-34. PubMed ID: 7193021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological properties of 2,3-dihydro-9H-isoxazolo[3,2-b]-quinazolin-9-one (W-2429. Part 2: General pharmacological investigation.
    Sofia RD; Diamantis W; Gordon R; Edelson J; Ludwig BJ
    Arzneimittelforschung; 1977; 27(4):782-9. PubMed ID: 405977
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.